There hasn't been any new medication for OCD since 1997. Biohaven is studying an investigational medication that modulates glutamate, and we want you to know more.
A new investigational treatment option for OCD
May receive study-related evaluations and medical care throughout trial
Be part of exciting progress in OCD treatment
Enter your information in the form below.
Choose the date and time that works best for us to give you a call.
We’ll call you at your scheduled time to discuss your eligibility, options & next steps.
Please fill out the form and schedule a time for us to contact you about this clinical trial.
By having this box checked, you agree to receive marketing messages from NOCD via email or text message. You can unsubscribe at any time.
Thanks for your interest in the study, please click below to determine your eligibility.
Biohaven Pharmaceuticals in New Haven, Connecticut, is the sponsor of the study. Biohaven researches a range of neurological disorders, and obsessive-compulsive disorder is an important focus of their work.
NOCD is a digital behavioral health company focused on identifying and treating OCD. NOCD is partnering with Biohaven to develop the first new medication for OCD since 1997.